Incyte Expands AI Drug Discovery Partnership with Genesis Molecular AI

Incyte (INCY) has expanded its partnership with Genesis Molecular AI under a $120 million deal aimed at accelerating the development of new small-molecule medicines using Genesis' GEMS platform. The collaboration includes Incyte sharing proprietary experimental data to enhance drug discovery efforts.

By Sara Sethiya, SA News Editor · Seeking Alpha · May 20, 2026, 12:54 UTC

Incyte Expands AI Drug Discovery Partnership with Genesis Molecular AI

Tickers: $INCY

Topics: AI in Drug Development Partnerships Pharmaceuticals

Read the full article at Seeking Alpha

More World news

Moderna Shares Decline Following Analyst Day Projections and Future Cost Concerns Motley Fool · November 12, 2026, 17:13 UTC
United Airlines Restricts AI Agent Access to Booking Systems Due to Cybersecurity and Regulatory Concerns TechCrunch · November 12, 2026, 17:17 UTC
Global Payments Shares Drop 12% Following Reports Private Equity Firms Abandoned Takeover Bid Seeking Alpha · November 12, 2026, 17:14 UTC
Nvidia Appoints Colette Kress as Interim CEO Following Jensen Huang's Resignation CNBC · November 12, 2026, 16:59 UTC
Brookfield Corporation Reports Strong Third Quarter Earnings Growth and Increased Share Buybacks Motley Fool · November 12, 2026, 17:08 UTC
Franco-Nevada Reports Q3 2026 Revenue Growth Driven by Higher Gold and Oil Prices Motley Fool · November 12, 2026, 17:10 UTC
Stratasys Reports Q3 2026 Revenue Growth Driven by Aerospace and Defense Demand Motley Fool · November 12, 2026, 17:11 UTC
Jim Cramer Advises Profit-Taking Following Jensen Huang's Resignation at Nvidia CNBC · November 12, 2026, 16:59 UTC
LexisNexis Report Shows Elevated U.S. Auto Insurance Shopping Volumes in Q3 2026 PR Newswire · November 12, 2026, 17:12 UTC
Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC